SCHEMBL3798531

SCHEMBL3798531

C=C(C)C(=O)OC(C)(O)C=Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.47
GLA P06280 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
EGFR P00533 1/20 0.40
ELANE P08246 1/20 0.38
NPC1 O15118 3/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
HDAC3 O15379 1/20 0.37
TNKS O95271 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27713538 0.81 CYP2C19 (0.43) CYP2C19GLATDP1EGFRELANE
SCHEMBL6858824 0.79 GLA (0.42) CYP2C19GLATDP1EGFRELANE
SCHEMBL3792651 0.78 PAM (0.41) CYP2C19GLATDP1EGFRELANE
Styrene SCHEMBL3400648 0.78 ALDH1A1 (0.45) CYP2C19GLATDP1EGFRELANE
SCHEMBL3431711 0.77 CYP3A4 (0.41) CYP2C19GLATDP1EGFRELANE
SCHEMBL393358 0.77 PAM (0.42) CYP2C19GLATDP1EGFRELANE
Styrene SCHEMBL9082414 0.75 ALDH1A1 (0.41) CYP2C19GLATDP1EGFRELANE
SCHEMBL4144000 0.74 GLA (0.45) CYP2C19GLATDP1EGFRNPC1
SCHEMBL1506495 0.74 APP (0.42) GLATDP1ALDH1A1MAPTHDAC3
Acrylonitrile SCHEMBL25380559 0.74 CYP2C19 (0.38) CYP2C19GLATDP1EGFRELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11567072-B2 Ligand bound MBP membranes, uses and method of manufacturing TERAPORE TECHNOLOGIES, INC. (US) 2023-01-31 US disclosed
CN-110785219-B Ligand-bound MBP membranes, uses and methods of manufacture 特拉波雷技术有限公司 2022-10-28 CN disclosed
US-20200232978-A1 LIGAND BOUND MBP MEMBRANES, USES AND METHOD OF MANUFACTURING TERAPORE TECHNOLOGIES, INC. (US) 2020-07-23 US disclosed
CN-110785219-A Ligand-bound MBP membranes, uses and methods of manufacture 特拉波雷技术有限公司 2020-02-11 CN disclosed
WO-2018156731-A1 LIGAND BOUND MBP MEMBRANES, USES AND METHOD OF MANUFACTURING DORIN RACHEL M (US) 2018-08-30 WO disclosed
US-8975327-B2 Controlling morphology of block copolymers DOW CORNING CORPORATION (US) 2015-03-10 US disclosed
US-20150064115-A1 NEUROPHILIC NANOPARTICLES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2015-03-05 US disclosed
EP-2643413-A1 CONTROLLING MORPHOLOGY OF BLOCK COPOLYMERS Dow Corning Corporation (US) 2013-10-02 EP disclosed
US-20130231438-A1 Controlling Morphology of Block Copolymers DOW CORNING CORPORATION (US) 2013-09-05 US disclosed
WO-2012071330-A1 CONTROLLING MORPHOLOGY OF BLOCK COPOLYMERS DOW CORNING CORPORATION (US) 2012-05-31 WO disclosed
WO-2008137733-A2 MICELLAR STRUCTURES, METHODS OF MAKING MICELLAR STRUCTURES, METHODS OF IMAGING, AND METHODS OF DELIVERING AGENTS EMORY UNIVERSITY (US) 2008-11-13 WO disclosed
WO-2008116044-A1 SEMICONDUCTOR QUANTUM DOTS FOR EFEICIENT DELIVERY AND INTRACELLULAR IMAGING OF SIRNA EMORY UNIVERSITY (US) 2008-09-25 WO disclosed
EP-1696784-A2 BIOCONJUGATED NANOSTRUCTURES, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF Emory University (US) 2006-09-06 EP disclosed
EP-1493015-A4 ANALYTE SENSOR POWERZYME INC (US) 2006-01-04 EP disclosed
WO-2005065081-A2 BIOCONJUGATED NANOSTRUCTURES, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF EMORY UNIVERSITY (US) 2005-07-21 WO disclosed
US-20050136258-A1 Nanoparticle fluorescent probes comprised of quantum dot and hydrophobic protection structure including capping ligand and amphiphilic copolymer; biocompatibility; multiplexed imaging and detection of genes and proteins in single living cells; cancer diagnosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-23 US disclosed
EP-1493015-A1 ANALYTE SENSOR Powerzyme, Inc. (US) 2005-01-05 EP disclosed
US-20040033206-A1 Hair treatment compositions containing at least one non-thickening amphiphilic diblock copolymer and at least one film-forming polymer which is beneficial for the hair L'OREAL (FR) 2004-02-19 US disclosed
US-20030228681-A1 Analyte sensor POWERZYME, INC. 2003-12-11 US disclosed
WO-2003087783-A1 ANALYTE SENSOR POWERZYME, INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033206-A1 Hair treatment compositions containing at least one non-thickening amphiphilic diblock copolymer and at least one film-forming polymer which is beneficial for the hair DSG1, CUTA, SHH CYP2C19 2682/4885GLA 2698/4885TDP1 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.